SOURCE: Genesis Biopharma

April 14, 2011 10:32 ET

Genesis Biopharma to Present at Aegis Capital Emerging Growth Conference in Las Vegas on April 29

LOS ANGELES, CA--(Marketwire - Apr 14, 2011) - Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer therapies, today announced its Chairman and CEO, Anthony J. Cataldo, will present at the Aegis Capital Emerging Growth Conference on Friday, April 29. The conference will take place between April 28 and April 30 at the Palazzo Hotel in Las Vegas.

Mr. Cataldo will discuss Genesis Biopharma's cancer therapeutic development programs including the company's GBP-102 anti-CD55+ therapeutic antibody development program, and emerging autologous cell therapy development program. GBP-102 is being investigated as a potential treatment for ovarian, GIST, and colorectal cancers. Genesis Biopharma's autologous cell therapy development program is initially focusing on the treatment of patients with metastatic melanoma.

Aegis Capital is a full-service retail and institutional broker-dealer with investment banking that specializes in financial services to companies with high growth potential.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit

Forward-Looking Statements

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Contact Information

  • Investor Contact:
    Laurel Moody
    Corporate Profile, LLC